Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 282,000 shares of common stock to seven new employees under the Company's 2024 Induc.

Business Wire • 11 hours ago

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

Sold all 3,185,000 shares of Immunome, estimated at $37.30 million based on quarterly average pricing Quarter-end position value decreased by $37.30 million, reflecting both stock price movement and the sale Represents a 4.92% decrease in Opaleye Management's 13F reportable assets under management Post-trade, Opaleye Management holds zero shares and zero dollar value in Immunome The position accounted for 5.3% of fund AUM in the prior quarter, marking a significant shift in portfolio composition

The Motley Fool • Mar 4, 2026

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. “Immunome made substantial progress in 2025. The positive Phase 3 RINGSIDE results represent a significant milestone for patients living with desmoid tumors and will support our planned NDA submission for varegacestat in.

Business Wire • Mar 3, 2026

Immunome to Present at Upcoming Investor Conferences

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference Presentation Date/Time: March 3, 2026, at 9:50 a.m. ET Leerink Partners Global Healthcare Conference Presentation Date/Time: March 10, 2026, at 3 p.m. ET Interested parties can ac.

Business Wire • Feb 23, 2026

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%

Redmile Group added 695,000 shares of Immunome last quarter; the estimated trade size was $12.20 million based on average prices for the quarter. The quarter-end position value increased by $64.01 million, reflecting both share purchases and price changes.

The Motley Fool • Feb 22, 2026

Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at Guggenheim's Emerging Outlook: Biotech Summit on February 11, 2026, at 9 a.m. ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be availabl.

Business Wire • Feb 4, 2026

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST. Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome's website at www.immunome.com. A replay webcast will b.

Business Wire • Jan 6, 2026

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat

Immunome (IMNM) delivered statistically significant phase 3 RINGSIDE results for varegacestat in progressive desmoid tumors, achieving an 84% risk reduction in progression or death compared to placebo. Varegacestat demonstrated a 56% objective response rate, the highest ever in a randomized desmoid tumor trial, and a marked reduction in tumor volume. I maintain a "Strong Buy" rating, supported by the upcoming NDA filing for varegacestat in Q2 2026 and IM-1021's phase 1 lymphoma data expected in 2026.

Seeking Alpha • Dec 17, 2025

Immunome Announces Pricing of Public Offering of Common Stock

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of $21.50 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and other offe.

Business Wire • Dec 17, 2025

Immunome's experimental drug meets main goal in late-stage study

Immunome said on Monday its experimental drug met main goal in a late-stage study for patients with a rare type of tumor.

Reuters • Dec 15, 2025